Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS)
CNY 81.2
(-2.84%)
CNY 81.2
(-2.84%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 394.21 Million CNY | 54.52% |
| 2022 | 255.11 Million CNY | 62.5% |
| 2021 | 156.99 Million CNY | 44.02% |
| 2020 | 109.01 Million CNY | -24.31% |
| 2019 | 144.02 Million CNY | -52.62% |
| 2018 | 303.96 Million CNY | 138.64% |
| 2017 | 127.37 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 570.05 Million CNY | 28.93% |
| 2024 Q2 | 442.14 Million CNY | 16.44% |
| 2024 Q1 | 379.71 Million CNY | -3.68% |
| 2023 Q4 | 394.21 Million CNY | 20.12% |
| 2023 FY | 394.21 Million CNY | 54.52% |
| 2023 Q3 | 328.18 Million CNY | 22.17% |
| 2023 Q1 | 220.81 Million CNY | -13.45% |
| 2023 Q2 | 268.63 Million CNY | 21.66% |
| 2022 Q2 | 113.5 Million CNY | 10.37% |
| 2022 Q1 | 102.83 Million CNY | -34.5% |
| 2022 Q4 | 255.11 Million CNY | 108.54% |
| 2022 FY | 255.11 Million CNY | 62.5% |
| 2022 Q3 | 122.33 Million CNY | 7.78% |
| 2021 Q2 | 114.6 Million CNY | 11.88% |
| 2021 Q3 | 102.13 Million CNY | -10.88% |
| 2021 FY | 156.99 Million CNY | 44.02% |
| 2021 Q1 | 102.42 Million CNY | -6.04% |
| 2021 Q4 | 156.99 Million CNY | 53.72% |
| 2020 Q1 | 41.43 Million CNY | -71.23% |
| 2020 FY | 109.01 Million CNY | -24.31% |
| 2020 Q4 | 109.01 Million CNY | 110.33% |
| 2020 Q3 | 51.82 Million CNY | 9.57% |
| 2020 Q2 | 47.3 Million CNY | 14.17% |
| 2019 FY | 144.02 Million CNY | -52.62% |
| 2019 Q4 | 144.02 Million CNY | 0.0% |
| 2019 Q1 | - CNY | 0.0% |
| 2018 FY | 303.96 Million CNY | 138.64% |
| 2017 FY | 127.37 Million CNY | 0.0% |